ipca
A dose of life

PRESS RELEASE

Ipca Laboratories Q3 FY15 Financial Results

Mumbai, February 7, 2015: Ipca Laboratories Limited today announced its unaudited standalone financial results for the third quarter ended 31st December, 2014.

Key Highlights of Q3 FY15

- Net Total Income down 11% at Rs. 747.09 crores.
- Domestic formulations income up 13% at Rs. 278.67 crores.
- Exports Income down 22% at Rs. 418.45 crores.
- EBIDTA margin @ 16.36 %.
- Net Profit at Rs. 41.53 crores down 70%.

Q3 FY15 at a glance			(Rs. Crores)
Particulars	**Q3 FY15**	**Q3 FY14**	**Growth**
Net Total Income	747.09	838.37	-11%
Export Income	418.45	533.77	-22%
EBITDA	121.14	217.34	-44%
EBITDA Margin	16.36%	26.09%	-
Profit before Forex (gain) / loss and tax	79.70	191.74	-58%
Forex (gain) / loss	11.15	2.42	-
Net Profit after Forex (gain) / loss and tax	41.53	139.12	-70%
Earnings per share of Rs. 2/- each (Rs.)	3.29	11.02	-70%

Ipca Laboratories Limited

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613
E: ipca@ipca.com CIN: L24239MH1949PLC007837

ipca
A dose of life

Q3 FY15 Revenue break-up			(Rs. Crores)
Particulars	**Q3 FY15**	**Q3 FY14**	**Growth**
Formulations			
Domestic	278.67	246.33	13%
Exports	305.09	388.64	-21%
Total Formulations	**583.76**	**634.97**	**-8%**
APIs			
Domestic	37.01	41.89	-12%
Exports	113.36	145.13	-22%
Total APIs	**150.37**	**187.02**	**-20%**
Grand Total	**734.13**	**821.99**	**-11 %**

Key Highlights of 9 months FY15

- Net Total Income down 1% at Rs. 2478.65 crores.
- Domestic formulations income up 16% at Rs. 899.77 crores.
- Exports Income down 11% at Rs. 1391.76 crores.
- EBIDTA margin @ 19.81%.
- Net Profit at Rs. 248.32 crores down 27%.

9 months FY15 at a glance			(Rs. Crores)
Particulars	**9 months FY15**	**9 months FY14**	**Growth**
Net Total Income	2478.65	2500.41	-1%
Export Income	1391.76	1555.36	-11%
EBITDA	486.83	622.89	-22%
EBITDA Margin	19.81%	25.06%	-
Profit before Forex (gain) / loss and tax	371.41	544.88	-32%
Forex (gain) / loss	18.25	90.29	-
Net Profit after Forex (gain) / loss and tax	248.32	340.34	-27%
Earnings per share of Rs. 2/- each (Rs.)	19.68	26.97	-27%

Ipca Laboratories Limited

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613
E: ipca@ipca.com CIN: L24239MH1949PLC007837

ipca
A dose of life

9 months FY15 Revenue break-up (Rs. Crores)			
Particulars	**9 months FY15**	**9 months FY14**	**Growth**
Formulations			
Domestic	899.77	772.86	16%
Exports	999.04	1088.67	-8%
Total Formulations	**1898.81**	**1861.53**	**2%**
APIs			
Domestic	145.67	128.01	14%
Exports	392.72	466.69	-16%
Total APIs	**538.39**	**594.70**	**-9%**
Grand Total	**2437.20**	**2456.23**	**-1%**

About Ipca Laboratories:

Ipca is a fast growing pharmaceutical company with a strong thrust on exports which now account for 56% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients

Ipca Laboratories Limited

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Standalone Financial Results

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22-62106050